Mobia Medical, Inc.
No enriched coverage for $MOBI in the last 7 days.
Mobia Medical (MOBI) announced that its Vivistim Paired VNS System, the only FDA-approved device for this treatment, was included in the 2026 AHA stroke recovery guidelines. The guidelines recognize paired VNS as an option to improve upper-limb function in chronic stroke survivors. MOBI's stock is up 7.17% in pre-market trading at $11.36.
Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.
Tansey Casey M purchased 16,441 shares of Mobia Medical, Inc. (MOBI) at $12.07 ($0.20M total) on 2026-08-18.
Recent MOBI coverage spans market movers, insider activity and earnings.
In the last 30 days, MOBI insiders filed 5 SEC Form 4 transactions — 5 purchases ($996K) and no sales. The most active reporter was Tansey Casey M with 5 filings.
Potential increase in adoption and sales of Mobia's Vivistim system.
The American Heart Association's stroke‑rehab guideline endorsement is a fresh, material catalyst that could boost demand for Mobia's Vivistim system.
Insider purchase signals confidence from a board member, but the amount is modest relative to float.
The earnings call provides fresh operating metrics (territories, units) plus updated full-year revenue guidance, which can drive near-term estimate revisions.
This is a disclosed insider open-market purchase, which can be read as bullish sentiment but is not a fundamental catalyst by itself.
alphai scores every news story that mentions MOBI with an AI model for sentiment and relevance, and aggregates insider trades from Mobia Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mobia Medical (MOBI) announced that its Vivistim Paired VNS System, the only FDA-approved device for this treatment, was included in the 2026 AHA stroke recovery guidelines. The guidelines recognize paired VNS as an option to improve upper-limb function in chronic stroke survivors. MOBI's stock is up 7.17% in pre-market trading at $11.36.
2 min readMobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.
1 min readTansey Casey M purchased 16,441 shares of Mobia Medical, Inc. (MOBI) at $12.07 ($0.20M total) on 2026-08-18.
1 min readMobia Medical (MOBI) reported Q2 2026 revenue of $13.5M, up 102% YoY, driven by Vivistim system adoption. Full-year guidance set at $54M-$56M. Net loss was $21M, with cash reserves of $177.1M post-IPO. Management plans to expand active territories and target 1,500 U.S. stroke centers.
7 min readTansey Casey M purchased 68,559 shares of Mobia Medical, Inc. (MOBI) at an average of $11.63 ($11.51–$12.53, $0.80M total) across 4 trades over 2026-08-13 to 2026-08-17.
2 min readMobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Second Quarter 2026 Financial Results Austin, Texas, August 11, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial re
4 min readMobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Election of Directors. Effective July 30, 2026, the Board of Directors (the “ Board ”) of Mobia Medical, Inc. (“ Mobia
2 min readMobia Medical, Inc. (Nasdaq: MOBI) said it appointed Reza Zadno, Ph.D., as an independent director effective July 14, 2026. Zadno will also sit on the Compensation Committee. The company cited his experience leading public medical technology firms through IPOs and commercial expansion, including roles at PROCEPT BioRobotics and Avedro.
2 min readMobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001489993 false 0001489993 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14,
2 min readMobia Medical (Nasdaq: MOBI) said Neurology published two-year follow-up results from its VNS-REHAB trial of Vivistim Paired VNS Therapy in chronic ischemic stroke. Among 49 participants, 76% met response on FMA-UE and/or WMFT, with average gains of +7.5 FMA-UE and +0.63 WMFT. Mobia reported improvements in daily living and quality of life sustained for at least two years.
4 min read
